(Q73786509)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

6 November 2019

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Miguel A Sanz

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

J Sierra

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M Gandarillas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M D Caballero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J Marín

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J J Lahuerta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J García-Conde

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Arranz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A León

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J Zuazu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J García-Laraña

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A López-Guillermo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Grañena

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J C García

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

E Conde

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

GEL/TAMO Spanish Cooperative Group

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 February 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

405-412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313670%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702795

6 November 2019

exact match

0 references

cites work

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702795

7 January 2021